Skip to main content

Advertisement

ADVERTISEMENT

News

News
02/23/2022
Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions
Results of CTO-PCI IDE Study Demonstrate Procedural Success with Teleflex Specialty Catheters and Coronary Guidewires in Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Interventions
Results of CTO-PCI IDE Study...
02/23/2022
Cath Lab Digest
News
02/22/2022
Libby™ IAAA’s groundbreaking AI and cloud-based technology aids Intravascular Optical Coherence Tomography image analysis
Libby™ IAAA’s groundbreaking AI and cloud-based technology aids Intravascular Optical Coherence Tomography image analysis
Libby™ IAAA’s groundbreaking AI...
02/22/2022
Cath Lab Digest
News
02/18/2022
The FDA cleared and Health Canada approved 4 French REBOA device saves valuable time by controlling bleeding in situations of traumatic injury and severe hemorrhage
The FDA cleared and Health Canada approved 4 French REBOA device saves valuable time by controlling bleeding in situations of traumatic injury and severe hemorrhage
The FDA cleared and Health...
02/18/2022
Cath Lab Digest

Advertisement

News
02/17/2022
First-of-its kind metal-alloy angioplasty scoring sheath effective in treatment of critical arterial stenosis.
First-of-its kind metal-alloy angioplasty scoring sheath effective in treatment of critical arterial stenosis.
First-of-its kind metal-alloy...
02/17/2022
Cath Lab Digest
News
02/16/2022
Propelled by advancements, the global stroke management market is poised to account for a valuation of $48.5 billion USD over the span of 2021-2027.
Propelled by advancements, the global stroke management market is poised to account for a valuation of $48.5 billion USD over the span of 2021-2027.
Propelled by advancements, the...
02/16/2022
Cath Lab Digest
News
02/16/2022
NEW ORLEANS – Every 36 seconds, an American dies of cardiovascular disease, meaning that in this pandemic, cardiovascular disease is still a very real threat. The New Cardiovascular Horizons (NCVH) conference is returning to New Orleans this...
NEW ORLEANS – Every 36 seconds, an American dies of cardiovascular disease, meaning that in this pandemic, cardiovascular disease is still a very real threat. The New Cardiovascular Horizons (NCVH) conference is returning to New Orleans this...
NEW ORLEANS – Every 36 seconds,...
02/16/2022
Vascular Disease Management

Advertisement

News
02/14/2022
Small study of long COVID patients experienced symptom improvement following EECP therapy
Small study of long COVID patients experienced symptom improvement following EECP therapy
Small study of long COVID...
02/14/2022
Cath Lab Digest
News
02/11/2022
February 11, 2022 — SIRONA is the world’s first and the largest head-to-head randomized, controlled trial (RCT) investigating the use of a sirolimus drug-coated balloon (DCB) (Magic Touch PTA – Concept Medical) vs a paclitaxel DCB (CE...
February 11, 2022 — SIRONA is the world’s first and the largest head-to-head randomized, controlled trial (RCT) investigating the use of a sirolimus drug-coated balloon (DCB) (Magic Touch PTA – Concept Medical) vs a paclitaxel DCB (CE...
February 11, 2022 — SIRONA...
02/11/2022
Cath Lab Digest
News
02/10/2022
A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA) outcomes when surgeon volume is greater than seven cases yearly and performed in hospitals with a 30-day mortality rate less than 5%.
A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA) outcomes when surgeon volume is greater than seven cases yearly and performed in hospitals with a 30-day mortality rate less than 5%.
A multicenter, retrospective...
02/10/2022
Cath Lab Digest

Advertisement

News
02/08/2022
Phase 2a clinical trial evaluating REG-101 for PAD expected to initiate second half of 2022
Phase 2a clinical trial evaluating REG-101 for PAD expected to initiate second half of 2022
Phase 2a clinical trial...
02/08/2022
Cath Lab Digest

Advertisement